| Literature DB >> 28501848 |
Jianxi Zhao1, Gang Ren1, Rong Cai2, Jian Chen1, Huali Li1, Chen Guo1, Wenguang He1, Xiangru Wu3, Wenjie Zhang4.
Abstract
Mucinous gastric carcinoma (MGC) is a rare histological subtype of gastric cancer. The clinicopathological characteristics and CT features of MGC remain controversial. This study aimed to determine the clinicopathological characteristics and CT features of MGC. We reviewed 62 patients with MGC and 104 patients with non-mucinous gastric carcinoma (NMGC), pathologically confirmed between 2003 and 2015. There are significant differences in some clinicopathological characteristics and CT features between MGC and NMGC. NMGC occurs preferentially in males and more frequently in the lower third of the stomach. Patients with MGC were characterized by larger tumor size, more advanced tumor stages (II and III) and fewer lymphatic invasions. Layered enhancement (83.3%) was the main pattern of MGC, while the most common pattern in NMGC was homogeneous enhancement (52.6%), followed by heterogonous enhancement (34.6%). The degree of enhancement of the inner layer in MGC was significantly higher than in NMGC (ΔCT of portal venous phase: 54.57 Hu vs. 47.19 Hu, P = 0.034), while the middle or outer layer in MGC was significantly less enhanced (ΔCT of portal venous phase: 19.07 Hu vs. 33.09 Hu, P <0.001). Calcifications were more common in MGC (P <0.001). ROC curves revealed that the most effective variables in distinguishing MGC and NMGC were ΔCT of the middle or outer layer in the arterial phase (AUC=0.774) and portal venous phase (AUC=0.774), followed by the attenuation value of the middle or outer layer in the unenhanced phase (AUC=0.763). Calcifications had a high specificity (98.7%) in the diagnosis of MGC. The accuracy (86.1%), sensitivity (83.3%) and specificity (87.2%) of layered enhancement in diagnosing MGC were all high. Therefore, MGC was more likely to have larger tumor size and more advanced tumor stage (II and III) than NMGC. The thicker gastric wall, layered enhancement pattern and calcification were highly suggestive CT features for differentiating MGC from NMGC.Entities:
Keywords: clinicopathological characteristics; computed tomography; mucinous gastric carcinoma; non-mucinous gastric carcinoma
Mesh:
Substances:
Year: 2017 PMID: 28501848 PMCID: PMC5542219 DOI: 10.18632/oncotarget.17389
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Comparison of clinicopathological characteristics between MGC and NMGC
| Clinicopathological variables | MGC | NMGC | P value |
|---|---|---|---|
| N (%) or mean±SD | N (%) or mean±SD | ||
| Age, years | 0.202 | ||
| <60 | 27(43.5) | 35(33.7) | |
| ≥60 | 35(56.5) | 69(66.3) | |
| Gender | 0.006 | ||
| Male | 41(66.1) | 88(84.6) | |
| Female | 21(33.9) | 16(15.4) | |
| Tumor location | 0.002 | ||
| Upper | 16(25.8) | 29(27.9) | |
| Middle | 22(35.5) | 12(11.5) | |
| Lower | 23(37.1) | 61(58.7) | |
| Whole | 1(1.6) | 2(1.9) | |
| Tumor size, cm | 6.93±4.41 | 4.11±2.24 | <0.001 |
| CEA, ng/ml | 0.561 | ||
| <10 | 9(18.0) | 13(14.3) | |
| ≥10 | 41(82.0) | 78(85.7) | |
| CA 19-9, U/ml | 0.105 | ||
| <39 | 16(32.0) | 18(19.8) | |
| ≥39 | 34(68.0) | 73(80.2) | |
| Macroscopic type | <0.001 | ||
| Type 0 | 1(1.6) | 26(25) | |
| Type 1 | 7(11.3) | 4(3.8) | |
| Type 2 | 35(56.5) | 51(49.0) | |
| Type 3 | 11(17.7) | 18(17.3) | |
| Type 4 | 8(12.9) | 5(4.8) | |
| pT staging | 0.001 | ||
| T1 | 1(1.6) | 26(25) | |
| T2 | 9(14.5) | 14(13.5) | |
| T3 | 17(27.4) | 18(17.3) | |
| T4 | 35(56.5) | 46(44.2) | |
| pN staging | 0.441 | ||
| N0 | 19(30.6) | 44(42.3) | |
| N1 | 11(17.7) | 17(16.3) | |
| N2 | 12(19.4) | 19(18.3) | |
| N3 | 20(32.3) | 24(23.1) | |
| pM staging | 0.542 | ||
| M0 | 60(96.8) | 97(93.3) | |
| M1 | 2(3.2) | 7(6.7) | |
| pTNM staging | 0.026 | ||
| I | 6(9.7) | 31(29.8) | |
| II | 19(30.6) | 26(25.0) | |
| III | 34(54.8) | 42(40.4) | |
| IV | 3(4.8) | 5(4.8) | |
| Lymphatic invasion | 0.011 | ||
| Positive | 6(9.7) | 27(26.0) | |
| Negative | 56(90.3) | 77(74.0) | |
| Venous invasion | 0.293 | ||
| Positive | 3(4.8) | 1(1.0) | |
| Negative | 59(95.2) | 103(99.0) | |
| Neural invasion | 0.224 | ||
| Positive | 5(8.1) | 15(14.4) | |
| Negative | 57(91.9) | 89(85.6) |
CEA: carcinombryonic antigen
CA 19-9: glycoprotein antigens 19-9
SD: standard deviation
Comparison of CT features between advanced MGC and NMGC
| Variables of CT features | MGC | NMGC | P value |
|---|---|---|---|
| N (%) or mean±SD | N (%) or mean±SD | ||
| Wall thickness, cm | 1.75±0.52 | 1.35±0.37 | <0.001 |
| Upper | 1.68±0.36 | 1.38±0.39 | 0.072 |
| Middle | 1.50±0.51 | 1.36±0.41 | 0.535 |
| Lower | 1.84±0.45 | 1.30±0.35 | <0.001 |
| Whole | 3.10 | 1.93±0.05 | 0.033 |
| Attenuation value of the inner layer, HU | |||
| Unenhanced phase | 34.93±6.75 | 40.77±7.28 | <0.001 |
| Arterial phase(ΔCT) | 17.70±14.90 | 23.19±14.27 | 0.080 |
| Portal venous phase(ΔCT) | 54.57±18.27 | 47.19±14.98 | 0.034 |
| Equilibrium phase(ΔCT) | 45.06±18.26 | 41.58±16.25 | 0.487 |
| Attenuation value of the middle or outer layer, HU | |||
| Unenhanced phase | 25.97±5.88 | 33.26±8.44 | <0.001 |
| Arterial phase(ΔCT) | 7.00±6.10 | 15.92±11.31 | <0.001 |
| Portal venous phase(ΔCT) | 19.07±10.05 | 33.09±16.13 | <0.001 |
| Equilibrium phase(ΔCT) | 18.72±9.50 | 30.55±15.96 | 0.002 |
| Enhancement pattern | <0.001 | ||
| Homogeneous | 2(6.7) | 41(52.6) | |
| Heterogeneous | 3(10.0) | 27(34.6) | |
| Layered | 25(83.3) | 10(12.8) | |
| Degree of enhancement | 1.000 | ||
| mild enhancement | 4(13.3) | 10(12.8) | |
| Obvious enhancement | 26(86.7) | 68(87.2) | |
| Calcification | <0.001 | ||
| Positive | 10(33.3) | 1(1.3) | |
| Negative | 20(66.7) | 77(98.7) | |
| Surface dimple or ulcer | 1.000 | ||
| Positive | 26(86.7) | 66(84.6) | |
| Negative | 4(13.3) | 12(15.4) |
Figure 1Contrast-enhanced computed tomography images of mucinous gastric carcinoma
(A) A 67-year-old female with the lesion in gastric antrum showed layered enhancement and centrally hypodense area which was so called “mucin pool”. (B) A 60-year-old female with gastric antral cancer showed layered enhancement with irregular calcifications in the “mucin pool”. (C) A 49-year-old female with cardiac carcinoma showed layered enhancement and numerous punctate calcifications.
Figure 3Contrast-enhanced computed tomography images of non-mucinous gastric carcinoma
(A) A 67-year-old male with cardiac carcinoma showed obviously homogenous enhancement without calcification. (B) A 56-year-old male with lesion in gastric antrum showed obviously heterogeneous enhancement without calcification.
Figure 2Contrast-enhanced computed tomography images of mucinous gastric carcinoma
(A) A 40-year-old male with cardiac carcinoma showed obviously heterogeneous enhancement. (B) A 73-year-old male with the lesion in gastric antrum showed obviously homogenous enhancement without calcifications.
Correlation between clinicopathological characteristics and CT features in MGC
| Wall thickness | P value | Enhancement pattern | P value | Calcification | P value | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| ≤2cm | >2cm | Homogeneous | Heterogeneous | layered | Yes | No | ||||
| Age, years | 1.000 | 0.602 | 0.442 | |||||||
| <60 | 10 | 4 | 0 | 2 | 12 | 6 | 8 | |||
| ≥60 | 11 | 5 | 2 | 1 | 13 | 4 | 12 | |||
| Tumor location | 0.299 | 0.012 | 0.275 | |||||||
| Upper | 5 | 2 | 0 | 1 | 6 | 4 | 3 | |||
| Middle | 7 | 1 | 2 | 1 | 5 | 1 | 7 | |||
| Lower | 9 | 5 | 0 | 0 | 14 | 5 | 9 | |||
| Whole | 0 | 1 | 0 | 1 | 0 | 0 | 1 | |||
| Macroscopic type | 0.617 | 0.198 | 0.939 | |||||||
| Type 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | |||
| Type 2 | 11 | 5 | 1 | 1 | 15 | 6 | 10 | |||
| Type 3 | 6 | 1 | 0 | 2 | 4 | 2 | 5 | |||
| Type 4 | 3 | 2 | 0 | 0 | 5 | 1 | 4 | |||
| pT staging | 0.809 | 0.040 | 0.335 | |||||||
| T2 | 3 | 1 | 0 | 0 | 4 | 2 | 2 | |||
| T3 | 2 | 2 | 1 | 2 | 1 | 0 | 4 | |||
| T4 | 16 | 6 | 1 | 1 | 20 | 8 | 14 | |||
| pN staging | 0.333 | 0.123 | 0.675 | |||||||
| N0 | 9 | 1 | 1 | 0 | 9 | 2 | 8 | |||
| N1 | 3 | 2 | 0 | 2 | 3 | 2 | 3 | |||
| N2 | 2 | 2 | 1 | 0 | 3 | 1 | 3 | |||
| N3 | 7 | 4 | 0 | 1 | 10 | 5 | 6 | |||
| pM staging | 0.300 | 1.000 | 0.333 | |||||||
| M0 | 21 | 8 | 2 | 3 | 24 | 9 | 20 | |||
| M1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | |||
| pTNM staging | 0.168 | 1.000 | 0.274 | |||||||
| I | 3 | 0 | 0 | 0 | 4 | 1 | 2 | |||
| II | 7 | 3 | 1 | 1 | 6 | 2 | 7 | |||
| III | 11 | 4 | 1 | 2 | 13 | 5 | 11 | |||
| IV | 0 | 2 | 0 | 0 | 2 | 2 | 0 | |||
| lymphatic invasion | 0.287 | 0.287 | 1.000 | |||||||
| Positive | 4 | 0 | 1 | 0 | 3 | 1 | 3 | |||
| Negative | 17 | 9 | 1 | 3 | 22 | 9 | 17 | |||
| Venous invasion | 1.000 | 1.000 | 0.333 | |||||||
| Positive | 1 | 0 | 0 | 0 | 1 | 1 | 0 | |||
| Negative | 20 | 9 | 2 | 3 | 24 | 9 | 20 | |||
| Neural invasion | 0.563 | 1.000 | 1.000 | |||||||
| Positive | 2 | 2 | 0 | 0 | 4 | 1 | 3 | |||
| Negative | 19 | 7 | 2 | 3 | 21 | 9 | 17 | |||
Figure 4ROC curves of MDCT features
(A) Unenhanced: Attenuation value of the middle or outer layer in unenhanced phase; arterial: ΔCT of the middle or outer layer in arterial phase; portal: ΔCT of the middle or outer layer in portal venous phase. (B) ROC curve of ΔCT of the middle or outer layer in equilibrium phase. (C) ROC curve of thickness.
Parameters of ROC curves
| Parameters | AUC | Optimal threshold | Standard error | 95% CI | |
|---|---|---|---|---|---|
| Upper bound | Lower bound | ||||
| Wall thickness | 0.734 | 1.53 | 0.053 | 0.838 | 0.630 |
| Attenuation value of the middle or outer layer in unenhanced phase | 0.765 | 28.5 | 0.048 | 0.859 | 0.671 |
| ΔCT of the middle or outer layer in arterial phase | 0.774 | 11.5 | 0.048 | 0.868 | 0.679 |
| ΔCT of the middle or outer layer in portal venous phase | 0.774 | 19.5 | 0.048 | 0.869 | 0.679 |
| ΔCT of the middle or outer layer in equilibrium phase | 0.724 | 28.5 | 0.071 | 0.863 | 0.585 |
ROC: receiver operating characteristic curve
AUC: area under the curve
CI: confidence interval
The diagnostic efficiency of MGC by layered enhancement and calcification
| Accuracy (%) | Sensitivity (%) | Specificity (%) | P value | |
|---|---|---|---|---|
| Layered enhancement | 86.1 | 83.3 | 87.2 | <0.001 |
| Calcification | 80.6 | 33.3 | 98.7 | <0.001 |
| Layered enhancement and calcification | 81.5 | 33.3 | 100 | <0.001 |
| Layered enhancement or calcification | 85.2 | 83.3 | 85.9 | <0.001 |